Last reviewed · How we verify
Momelotinib treatment
Momelotinib treatment is a Small molecule drug developed by Groupe Francophone des Myelodysplasies. It is currently in Phase 2 development.
At a glance
| Generic name | Momelotinib treatment |
|---|---|
| Sponsor | Groupe Francophone des Myelodysplasies |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (EARLY_PHASE1)
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (PHASE4)
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (PHASE1)
- Momelotinib During and After HCT in Myelofibrosis (PHASE1)
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (PHASE2)
- Momelotinib in VEXAS Syndrome (PHASE2)
- Momelotinib Effectiveness in Myelofibrosis
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Momelotinib treatment CI brief — competitive landscape report
- Momelotinib treatment updates RSS · CI watch RSS
- Groupe Francophone des Myelodysplasies portfolio CI
Frequently asked questions about Momelotinib treatment
What is Momelotinib treatment?
Momelotinib treatment is a Small molecule drug developed by Groupe Francophone des Myelodysplasies.
Who makes Momelotinib treatment?
Momelotinib treatment is developed by Groupe Francophone des Myelodysplasies (see full Groupe Francophone des Myelodysplasies pipeline at /company/groupe-francophone-des-myelodysplasies).
What development phase is Momelotinib treatment in?
Momelotinib treatment is in Phase 2.